Health

Biotherapeutics Cell Line Development Market is Expected to Reach a value of US$100 mn by 2022

Press Release

Experts at Transparency Market Research (TMR) have presented their recent report on global biotherapeutics cell line development market. According to their analysis, the market is majorly dominated by two prominent players namely, Beckman Coulter and Becton Dickenson and company. These organizations holds a sizeable share of more than 85% of total biotherapeutics cell line development market.

As a result of the massive shareholding by these two players, the entry of any new organizations has become quite challenging. In order to have a successful establishment in the market, the new players are looking forward to mergers and collaborations with various businesses. These strategic developments are allowing the new players to possess enough resources and man-power to compete against well-established and already successful giants. Few new players are also acquiring various small and medium-scale businesses, in order to expand their brand value across the global biotherapeutics cell line development market.

Request A Sample-

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8272

Apart from the two dominating businesses of the global biotherapeutics cell line development market there are few other companies that are influencing the dynamics of the market. They are ProBiaGen AG, Sony Biotechnology Inc., CMC Biologics, Lonza Group Ltd., and Sysmex Partec GmbH.

According to the TMR report, the global biotherapeutics cell line development market worth US$56 mn at the end of 2014. However, the market is projected to worth approximately US$100 mn by the end of 2022. The market shall reach this value with a CAGR of 7.5% during the forecast period of 2015 to 2022.

Request Brochure-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8272

There are two processes on the basis of which the global biotherapeutics cell line development market is segmented. These processes are transfection and selection. Out of these two processes, the transfection process is prognosticated to be the most successful segment of global biotherapeutics cell line development market.

Geographically, Asia Pacific shall lead the global biotherapeutics cell line development market. The growth of region is a collective result of colossal untouched medical needs in various countries of the region. Also, the constant rise in various chronic disease medications is also one of the reasons that is supporting the growth of the region in biotherapeutics cell line development market.

Treatment of Chronic Diseases and Various Cancers to Promote the Growth of the Market 

The growing importance of biotherapeutics in the treatment of chronic diseases likes arthritis and diabetes is one of the prominent reasons that is promoting the growth of global biotherapeutics cell line development market in the forecast period. The treatment of various cancers also requires biotherapeutics treatment. This is yet another reason that is supporting the market growth. Moreover, the rising demand of protein-based therapeutics either approved or in developmental phase is also bolstering the demand for biotherapeutics cell line development in the market across the globe.

Growing number of geriatric population in various countries across the globe has raised the number of chronic disease cases globally. This has become a major factor that is promoting the global biotherapeutics cell line development market growth.

Strict Regulatory Frameworks to Hinder the Growth of Market 

As a result of strict regulatory framework encompassing various cell culture procedures, the market may find slight degradation of the growth in the forecast period. However, considerable efforts to launch the biotherapeutical drugs, in various developed regions, and heavy investments in research and development by various businesses shall help them to overcome the roadblocks and help the global biotherapeutics market to grow substantially during the forecast period of 2015 to 2022.

This post was originally published on The Market Plan